Hamdy Ahmed MD's Form 4 filing
Vincerx Pharma, Inc. (VINC) · filed Aug 10, 2023
- Accession no.
- 0000950170-23-041517
- Filed
- Aug 10, 2023
- Trade date
- Aug 9-10, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $21.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamdy Ahmed MDCIK 0001458506 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a weighted average purchase price. Actual purchase prices ranged from $0.88 to $0.95 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.
Referenced by the price of 1 transaction in Table I.
- F2
Represents actual price.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Operations Officer